NICE recommendation of darolutamide plus hormone therapy for metastatic prostate cancer offers around 6000 patients in ...
Prostate cancer screening for men over 70 is complex, with current recommendations against routine PSA testing due to slow ...
MedPage Today on MSN
Add-On Radioligand Therapy Slows Metastatic Hormone-Sensitive Prostate Cancer
Targeting prostate-specific membrane antigen, Lu-PSMA-617 has demonstrated clinical benefits in patients with PSMA-positive ...
BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen ...
GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...
NICE recommends Bayer’s Nubeqa® (darolutamide) plus androgen deprivation therapy as a treatment option for patients with hormone-sensitive metastatic prostate cancer Nubeqa® (darolutamide) plus ...
The National Institute for Health and Care Excellence (NICE) has recommended darolutamide in combination with androgen ...
GSK plc ( NYSE: GSK) and Syndivia on Monday announced an agreement granting GSK exclusive worldwide rights to develop and ...
Fresh from a European cancer conference that was all about antibody-drug conjugates (ADCs), GSK has turned to French biotech ...
A Biden spokeswoman confirmed the former president finished several weeks of radiation therapy treatment Monday.
Phase 3 ARENSENS clinical trial results were presented at JADPRO 2025, indicating darolutamide plus ADT improved rPFS in prostate cancer.
The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback